Pharma’s misdeeds could benefit NIH under proposed bill Capitol Connection February 24, 2015 Senator Elizabeth Warren (D-MA) recently proposed a "swear jar" system that will fine large drug companies for breaking laws and give this money to the National Institutes of Health (NIH). Could this so-called Medical Innovation Act help solve the NIH’s funding woes? Will a name change make NIH research center less controversial? Capitol Connection February 19, 2015 A controversial National Institutes of Health center has a new name. The National Center for Complementary and Alternative Medicine (NCCAM) is now the National Center for Complementary and Integrative Health (NCCIH). Could a name change help give the center more credibility? Power Shift: Science and the 114th Congress Podcast January 00, 1970 Change has come to the halls of Congress. The midterm elections ushered in a new wave of representation, and leaders of the Republican House and Senate have been busy selecting committee chairs and laying out their agendas. How will these changes impact science? What if we funded biomedical research like we fund stadiums? Capitol Connection January 28, 2015 A new study finds that the rate of investment in medical research is increasing across the globe but is actually declining in the United States. This decrease is causing a logjam in translating basic biological studies into products and treatments that can be used in clinical settings. Could new financial models—like biomedical research bonds—help fill this funding gap? Yet another committee says postdoc training needs overhaul Yet another committee says postdoc training needs overhaul Driving Force January 6, 2015 A new report issued by the National Academies details the continuing problems with postdoctoral training and issues some blunt recommendations for finally changing the status quo. A tribute to AAAS Fellow Joseph F. Coates The science of looking ahead: A tribute to AAAS Fellow Joseph F. Coates Tuesday, November 4, 2014 Some people just see farther. For a “consulting futurist,” foresight would seem to be mandatory. For AAAS Fellow Joseph F. Coates, who died October 16 at age 85, the scientific study of what’s beyond the visible horizon yielded a career that combined brilliance, effrontery and a legion of devotees.   Francesca Grifo is shaking up the EPA Francesca Grifo, an advocate for scientific integrity Member Spotlight November 25, 2014 Last year, AAAS Fellow Francesca Grifo became the first scientific integrity officer at the U.S. Environmental Protection Agency (EPA). Tasked with a 2009 directive from the president, she is driving out the engrained political pressure that has seeped into the agency’s scientific endeavors, an issue spotlighted during the George W. Bush administration. The Union of Concerned Scientists alleged the president’s administration sought out and exploited uncertainties in climate change science, while altering EPA reports and excluding scientists from environmental policy decisions. The Markup: R&D appropriations for FY 2015 Podcast January 00, 1970 The Markup with Matt Hourihan is a new series of occasional updates on science funding in Congress, featuring AAAS’s resident R&D budget guru. In this premiere edition, Hourihan runs down how science funding has fared in the current appropriations cycle. Antibiotic resistance: Will policymakers resist effective strategies? Antibiotic resistance: Will policymakers resist effective strategies? Capitol Connection October 14, 2014 One of the most pressing scientific issues facing Congress today is the risk that antibiotic resistance presents to human health. Unlike other political-scientific hot potatoes, such as global warming, the House and Senate crossed the aisle to pass a bipartisan bill to speed new antibiotics to market, and are working on a new bill to make FDA approval even easier. Could an open-access database speed up drug development? Could an open-access database speed up drug development? Capitol Connection October 6, 2014 A recent study finds a significant logjam in the development of new drugs at the discovery and early preclinical phases. Could the creation of an open-source translational research database help solve the problem?